Goserelin (Goserelinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists

Antineoplastic hormonal agents and hormone antagonists

Included in the formulation
  • Zoladex®
    capsules PC 
    AstraZeneca UK Ltd     United Kingdom
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    ONLS

    VED

    АТХ:

    L.02.A.E.03   Goserelin

    Pharmacodynamics:

    Synthetic analogue gonadotropin releasing hormone, with intermittent application stimulates, with constant - inhibits synthesis luteinizing and follicle-stimulating hormones in the anterior pituitary gland. Reduces the concentration of testosterone in the blood plasma of men, estradiol - in women. Effective in hormone-dependent prostate, breast, and uterine myoma and endometriosis.

    Pharmacokinetics:

    After subcutaneous administration, the maximum concentration in the blood plasma is achieved in 2-3 hours. The connection with plasma proteins is 30%. Penetrates through the blood-brain and placental barrier, is found in breast milk.

    Metabolism in the liver.

    The half-life is 2.5 hours for women, 4.2 hours for men. Elimination by the kidneys.

    Indications:

    It is used to treat hormone-dependent prostate and breast cancers. Used for benign tumors: uterine myoma and endometriosis. It is used in the IVF protocol.

    ICD-10

    II.C50.C50   Malignant neoplasm of breast

    II.C60-C63.C61   Malignant neoplasm of prostate

    II.D10-D36.D25   Leiomyoma of the uterus

    XIV.N80-N98.N80   Endometriosis

    XXI.Z30-Z39.Z31.1   Artificial insemination

    XXI.Z40-Z54.Z51.4   Preparatory procedures for subsequent treatment, not elsewhere classified

    Contraindications:

    Age to 14 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Gout, polycystic ovary syndrome with IVF.

    Pregnancy and lactation:

    Recommendations for FDA - Category X. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously, in the anterior abdominal wall of 3.6 mg every 28 days or 10.8 mg every 12 days.

    The highest daily dose: 10.8 mg.

    The highest single dose: 10.8 mg.

    Side effects:

    Central and peripheral nervous system: dizziness, anxiety, fatigue, impaired blood flow to the brain, depression, hallucinations, paresthesia, in men - a syndrome of compression of the spinal cord.

    Respiratory system: upper respiratory tract infection, exacerbation of chronic obstructive pulmonary disease.

    Hemopoietic system: anemia.

    The cardiovascular system: lability of arterial pressure, arrhythmia, myocardial infarction, progression of chronic heart failure, peripheral blood supply disorders.

    Digestive system: decreased appetite, anorexia, diarrhea, or constipation.

    Musculoskeletal system: arthralgia, decreased bone mass, osteoporosis.

    Dermatological reactions: a rash.

    urinary system: in men - obstruction of the urinary tract.

    Reproductive system: decreased libido and potency, in women - dysmenorrhea, dryness in the vagina, polycystic ovaries.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Goserelin in a dose of 10.8 mg in women is not used.

    Instructions
    Up